Present report enumerates the vaccine potential of a glutathione-S-transferase purified from Setaria cervi against lymphatic filariasis. In jirds (Meriones unguiculatus) vaccination trial, a very significant 82.75% (p<0.005) reduction in adult parasite burden was observed in ScGST immunized group after 90 days post Brugia malayi L3 challenge. An inverse correlation between the antibody level and worm burden was found in ScGST immunized group (Person's correlation r=0.943, p<0.05). No recoveries of worms were obtained in heart and lungs of vaccinated group. The Antibodies reactive to ScGST appeared within four weeks of first dose and were able to neutralize the GST activity up to 86%. In an earlier study we have shown vaccine potential of ScGST against B. malayi by ADCC. Evaluation of cytokine profile in T-cells isolated from BALB/c mice immunized with ScGST were also showed predominance of Th2 response which further maintained the humoral immunity generated by ScGST administration in mice. The overall observations prompted us to envisage ScGST as a potential vaccine candidate against lymphatic filariasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2008.03.099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring barriers to accessing treatment for Lymphatic Filariasis through a socio-ecological lens in Buvuma and Napak districts, Uganda.
PLoS Negl Trop Dis
January 2025
International Lymphoedema Framework, London, United Kingdom.
Background: The World Health Organization launched the Global Programme to Eliminate Lymphatic Filariasis in 2000, which aimed at eradicating the disease by 2030. This goal depends on community mass drug administration and essential care. Despite these efforts, many rural communities still face untreated lymphatic filariasis and lack access to treatment and self-management.
View Article and Find Full Text PDFA new guide for basic psychological support for persons affected by neglected tropical diseases: A peer support tool suitable for persons with a diagnosis of leprosy and lymphatic filariasis.
PLoS Negl Trop Dis
January 2025
NLR | until No Leprosy Remains, Amsterdam, The Netherlands.
Background: People with disabilities due to neglected tropical diseases (NTDs), such as leprosy and lymphatic filariasis (LF), often encounter situations of stigma and discrimination that significantly impact their mental wellbeing. Mental wellbeing services are often not available at the peripheral level in NTD-endemic countries, and there is a need for such services. Basic psychological support for persons with NTDs (BPS-N) from peers is an important potential solution for addressing mental wellbeing problems.
View Article and Find Full Text PDFThe effects of variable spatial aggregation on lymphatic filariasis transmission.
Parasit Vectors
January 2025
National Centre for Epidemiology and Population Health, Australian National University, 62 Mills Road, Canberra, 2601, ACT, Australia.
Background: Elimination of lymphatic filariasis (LF) is a World Health Organization goal, with several countries at or near prevalence thresholds. Where LF cases remain after mass drug administration, they tend to be spatially clustered, with an overdispersed individual worm burden. Both individual and spatial heterogeneities can cause aggregation of infection; however, few studies have investigated the drivers of heterogeneity and implications for disease elimination.
View Article and Find Full Text PDFGenome-Wide Analysis Reveals Key Genes and MicroRNAs Related to Pathogenic Mechanism in .
Pathogens
December 2024
School of Artificial Intelligence, Hangzhou Dianzi University, Hangzhou 310018, China.
is a parasite transmitted by mosquitoes and can cause a neglected tropical disease called Lymphatic filariasis. However, the genome of was not well studied, making novel drug development difficult. This study aims to identify microRNA, annotate protein function, and explore the pathogenic mechanism of by genome-wide analysis.
View Article and Find Full Text PDFImplementation of Mass Drug Administration for Lymphatic Filariasis in Madagascar: The Progress, Effectiveness and Financial Savings of Integrating into an Existing Polio Campaign.
Res Rep Trop Med
December 2024
Madagascar Country Office, World Health Organization, Antananarivo, Madagascar.
Introduction: This paper presents (a) the progress made towards achieving the 2023 Lymphatic Filariasis (LF) Mass Drug Administration (MDA) campaign goals, (b) the estimated financial savings resulting from integrating LF MDA into Polio immunization campaigns, and (c) the best practices, challenges, and recommendations.
Methods: In 2023, 21,336,057 people in 83 districts were affected by LF and required Preventive Chemotherapy (PC). The National NTD Control Programme (NTDCP) conducted three phases of LF MDA campaigns in those districts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!